

SNX2 RABBIT PAB

货号: S220956

产品全名: SNX2 兔多抗

基因符号 TRG-9

UNIPROT ID: O60749 (Gene Accession - NP_003091)

背景: This gene belongs to the sorting nexin family whose members contain the phosphoinositide-binding phox (PX) domain. The encoded protein is a component of the retromer complex which plays a role in protein sorting in the endocytic pathway. This protein may form oligomeric complexes with other family members. Alternate splicing results in multiple transcript variants of this gene. Pseudogenes associated with this gene are located on chromosomes 1 and 7.

抗原: Synthetic peptide of human SNX2

经过测试的应用: ELISA, WB, IHC

推荐稀释比: IHC: 25-100;WB: 500-2000;ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 220956(SNX2 Antibody) at a dilution of 1/40(Cytoplasm).




In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 220956(Anti-SNX2 Antibody) at dilution 1/40.



The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using 220956(Anti-SNX2 Antibody) at a dilution of 1/40.



In comparison with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with synthetic peptide and then with D262282(Anti-SNX2 Antibody) at dilution 1/40.



Gel: 8%SDS-PAGE, Lysate: 40 µg;
Lane 1-4: NIH/3T3 cells, A549 cells, 293T cells, hela cells;
Primary antibody: 220956(SNX2 Antibody) at dilution 1/300;
Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution;
Exposure time: 10 seconds



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
